Scan­dion's shares fall af­ter on­col­o­gy biotech re­ports PhII fail

Dan­ish biotech Scan­dion On­col­o­gy post­ed some Phase II re­sults on Fri­day, and in­vestors were none too pleased.

The biotech re­port­ed topline re­sults from the sec­ond …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER